Label Changes for:
Zemplar (paricalcitol) 2 mcg/mL and 5 mcg/mL injection
August 2009
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- August 2009
ADVERSE REACTIONS
Postmarketing Experience
- angioedema (including laryngeal edema)

